Eli Lilly emphasizes the importance of GLP-1 medications.
Merck's acquisition of Terns Pharma is highlighted.
The newsletter covers various biotech developments.
Strategic angle: Eli Lilly discusses the 'societal obligation' of GLP-1s amidst other biotech news.
Eli Lilly emphasizes the importance of GLP-1 medications.
Merck's acquisition of Terns Pharma is highlighted.
The newsletter covers various biotech developments.